Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Drug

Jiangsu Hengrui’s Oteseconazole (SHR8008) Approved by NMPA for Severe Vulvovaginal Candidiasis

Fineline Cube Jun 29, 2023

The National Medical Products Administration (NMPA) has granted approval to China-based Jiangsu Hengrui Pharmaceuticals Co.,...

Company Deals

WestGene Biopharma Secures $42 Million in Funding to Advance mRNA Therapeutics

Fineline Cube Jun 29, 2023

Chengdu-based mRNA specialist WestGene Biopharma has reportedly raised USD 42 million via a funding round,...

Company Deals

Pfizer Partners with CSPC Pharmaceutical to Localize Paxlovid in China

Fineline Cube Jun 29, 2023

US pharmaceutical major Pfizer (NYSE: PFE) has entered into a partnership with China-based CSPC Pharmaceutical...

Company Drug

EOC Pharma’s Lusutrombopag Receives NMPA Approval for Chronic Liver Disease Treatment

Fineline Cube Jun 29, 2023

China-based EOC Pharma Group has announced that its drug, lusutrombopag, has received marketing approval from...

Company Deals

Changchun BCHT Biotechnology to Acquire Full Stake in mRNA R&D Firm Transcend Biomedical

Fineline Cube Jun 29, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced its intention to invest in...

Company Drug

Jiangsu Simcere’s Edaravone, Borneol Sublingual Tablets for AIS Accepted by NMPA for Review

Fineline Cube Jun 29, 2023

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that the National Medical Products Administration...

Company Drug

Shanghai Junshi Biosciences Gets FDA Approval for Phase III Study of Tifcemalimab in Small-Cell Lung Cancer

Fineline Cube Jun 29, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877) has announced receiving approval from the US Food...

Company Deals

Worg Pharmaceuticals Secures RMB 1.1 Billion in Series C Financing for Global Expansion

Fineline Cube Jun 29, 2023

Worg Pharmaceuticals, a Hangzhou-based developer of allergy drugs, has reportedly raised RMB 1.1 billion (USD...

Company Drug

AIM Vaccine Receives NMPA Approval for mRNA Vaccine Clinical Study Targeting COVID-19 Variants

Fineline Cube Jun 29, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...

Company Deals

Sichuan Kelun-Biotech Biopharmaceutical Prices IPO at HKD 60.6 to 72.8 per Share

Fineline Cube Jun 29, 2023

Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co.,...

Company Drug

Shandong Buchang Pharmaceuticals’ BC001 Gets Clinical Trial Approval for Solid Tumors

Fineline Cube Jun 29, 2023

Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a China-based pharmaceutical company, has announced receiving clinical...

Company Drug

Beijing Tiantan Biological Completes Phase I Study for Recombinant Coagulation Factor VIIa

Fineline Cube Jun 28, 2023

China-based Beijing Tiantan Biological Products Co., Ltd (SHA: 600161) has announced the conclusion of a...

Policy / Regulatory

Shanghai’s SMPA Notification: Non-Winning Bids in VBP Round 8 Can Avoid “Higher Price” Label

Fineline Cube Jun 28, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification concerning the 8th round of...

Company Legal / IP Policy / Regulatory

US FDA Issues Warning Letter to Chengdu KeCheng Fine Chemicals Over Communication Failures

Fineline Cube Jun 28, 2023

The US FDA’s Center for Drug Evaluation (CDE) issued a warning letter to China-based Chengdu...

Company Drug

Grand Pharmaceutical Initiates Phase I Study for TLX250-CDx in Renal Mass Imaging

Fineline Cube Jun 28, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...

Company Drug

Teva Pharmaceutical’s Copaxone Approved by NMPA for Multiple Sclerosis Treatment in China

Fineline Cube Jun 28, 2023

The National Medical Products Administration (NMPA) website has indicated that Israel-based Teva Pharmaceutical Industries’ (NYSE:...

Company

Fosun Pharmaceutical’s Sisram Opens Wellness Center in Chicago for Beauty and Health

Fineline Cube Jun 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the establishment of...

Company Deals

Sanyou Biopharmaceuticals and Huadong Medicine Expand Partnership on Macromolecule Therapeutics

Fineline Cube Jun 28, 2023

China-based Sanyou Biopharmaceuticals Co., Ltd has announced a licensing deal with compatriot firm Huadong Medicine...

Company Drug

Daewoong Pharmaceutical Files NDA in China for Potassium-Competitive Acid Blocker Fexuclu

Fineline Cube Jun 28, 2023

South Korea-based Daewoong Pharmaceutical (KRX: 069620) has revealed that a new drug application (NDA) has...

Company Drug

Insilico Medicine’s AI-Discovered Drug INS018_055 Reaches Phase II Clinical Trial Milestone

Fineline Cube Jun 28, 2023

China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has announced that its lead pipeline candidate,...

Posts pagination

1 … 455 456 457 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.